Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.53 |
| ▸ | CA2 | P00918 | 11/20 | 0.53 |
| ▸ | CA12 | O43570 | 9/20 | 0.52 |
| ▸ | CA9 | Q16790 | 9/20 | 0.52 |
| ▸ | CA4 | P22748 | 5/20 | 0.52 |
| ▸ | CA6 | P23280 | 5/20 | 0.52 |
| ▸ | CA5A | P35218 | 5/20 | 0.52 |
| ▸ | CA7 | P43166 | 5/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.52 |
| ▸ | CA3 | P07451 | 4/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.48 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587590 | 1.00 | CA1 (0.53) | CA1CA2CA12CA9CA4 | |
| Benzoic Acid SCHEMBL28509753 | 0.83 | ITGA1 (0.53) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2127269 | 0.82 | CA1 (0.53) | CA1CA2CA12CA9CA4 | |
| SCHEMBL29852349 | 0.82 | CA1 (0.53) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6335085 | 0.81 | AKR1B1 (0.56) | LMNATDP1AKR1B1TSHRCYP3A4 | |
| SCHEMBL1805099 | 0.80 | CA1 (0.50) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1463352 | 0.80 | CA1 (0.55) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1803685 | 0.80 | CA1 (0.50) | CA1CA2CA12CA9CA4 | |
| SCHEMBL5194623 | 0.80 | CA2 (0.52) | CA1CA2CA12CA9CA4 | |
| SCHEMBL28218707 | 0.80 | TSHR (0.54) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | claimed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | claimed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | claimed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | claimed |
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4229045-B1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BROAD INST INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | US | disclosed |
| EP-4229045-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2002087587-A2 | 4-AMINOSULFONYLQUINAZOLINES AND -QUINOLINES AS TYROSINE KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| US-6410749-B1 | REACTING A CARBONYL COMPOUND WITH ORGANOMETALLIC COMPOUND | NIPPON SODA CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1146037-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS | NIPPON SODA CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | disclosed |
| US-5270313-A | Treatment of circulatory disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0510526-A1 | Use of sulfonamides as drug and new sulfonamides | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | CA1 418/4885CA2 40/4885CA12 125/4885 |
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | CA1 2072/4885CA2 2985/4885CA12 2511/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | CA1 1716/4885CA2 2884/4885CA12 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.